Loading organizations...
§ Private Profile · Edinburgh, Edinburgh, United Kingdom
Biotechnology company develops small-molecule drugs for metabolic diseases like Type 2 Diabetes and NASH, targeting FFAR1 and FFAR4.
Caldan Therapeutics is a biotechnology company based in Nottingham and Glasgow, United Kingdom, that develops novel small-molecule therapeutics targeting free fatty acid receptors to treat metabolic diseases such as Type 2 Diabetes and non-alcoholic steatohepatitis (NASH). The enterprise operates as a university spin-out and has scaled its clinical operations to employ up to 17 staff members alongside three partner contract research organizations (CROs). To support its patent-protected chemistry programs, the firm successfully raised £8.15 million in total venture funding between its inception and 2020. This financial backing was provided by a syndicate of notable institutional investors, including Epidarex Capital, the Scottish Investment Bank, and Eli Lilly. Originating from collaborative research between the University of Glasgow and the University of Southern Denmark, the business was founded in 2015 by Professor Graeme Milligan and Professor Trond Ulven.
Caldan Therapeutics has raised $8.5M across 2 funding rounds.
Caldan Therapeutics has raised $8.5M in total across 2 funding rounds.
Caldan Therapeutics has raised $8.5M across 2 funding rounds. Most recently, it raised $1.8M Other Equity in August 2019.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Aug 29, 2019 | $1.8M Venture Round | Elizabeth Roper, David Holbrook | — | Announced |
| Nov 6, 2015 | $6.7M Series A | Epidarex Capital | Scottish Enterprise | Announced |
Caldan Therapeutics has raised $8.5M in total across 2 funding rounds.
Caldan Therapeutics's investors include Elizabeth Roper, David Holbrook, Epidarex Capital, Scottish Enterprise.